As widely reported over the last two weeks, EpiPen, which stops potentially fatal allergic reactions by injecting a precise dose of epinephrine, now costs about $600 for a two-pack, up from roughly $100 when Mylan acquired EpiPen in 2007. The Week summarizes the story in a piece called "The EpiPen uproar, explained," available here.
Today, more EpiPen news, when the New York's Attorney General announced that his office has opened a probe into whether Mylan Pharmaceuticals broke antitrust law in writing contracts to provide EpiPens to some schools systems. The NY AG's short press release is here. According to Reuters, "there had been allegations that schools which had used Mylan's EpiPen4Schools program, which gives many schools the devices for free, were contractually barred from buying products from Mylan competitors for a year. Senators Richard Blumenthal and Amy Klobuchar asked the Federal Trade Commission on Tuesday to investigate the allegation."
